Page 103 - Demo

Cannabidiol for severe behavioral manifestations in TSC, MPS III, and FXS1014References1. Woittiez, I., Putman, L., Eggink, E., Ras, M., & Sterkenburg PS. Zorg Beter Begrepen. Soc en Cult Planbureau [Internet]. 2014; Available from: http://pdf.swphost.com/Sozio/enieuwsbrief/2014/Zorg_beter_begrepen_drukversie.pdf.2. Hunt A. Tuberous sclerosis: a survey of 97 cases. Dev Med Child Neurol. 1983; 3. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research. 2015. 4. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018. 5. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014.6. Franco V, Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019. 7. GW Pharma Ltd. Epidyolex (cannabidiol) oral solution [Internet]. [cited 2023 May 9]. Available from: https://www.medicines.org.uk/ emc/product/10781.8. Tartaglia N, Bonn-Miller M, Hagerman R. Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. Cannabis and Cannabinoid Research. 2019. 9. Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019.10. Efron D, Taylor K, Payne JM, Freeman JL, Cranswick N, Mulraney M, et al. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial. BMJ Open. 2020.11. McLaren JL, Lichtenstein JD, Metcalfe JD, Charlot LR, Drake RE, Beasley JB. Psychotropic Use Among Youths With Intellectual and Developmental Disabilities. Psychiatr Serv. 2021.12. Deb S, Nancarrow T, Limbu B, Sheehan R, Wilcock M, Branford D, et al. UK psychiatrists’ experience of withdrawal of antipsychotics prescribed for challenging behaviours in adults with intellectual disabilities and/or autism. BJPsych Open. 2020;6(5). 13. Palumbo JM, Thomas BF, Budimirovic D, Siegel S, Tassone F, Hagerman R, et al. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. J Neurodev Disord. 2023;15(1):1–10. 14. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Vol. 19, International Journal of Molecular Sciences. 2018. 15. Webb DW, Osborne JP. Tuberous sclerosis. Archives of Disease in Childhood. 1995. 16. Crino PB, Nathanson KL, Henske EP. Medical progress: The tuberous sclerosis complex. N Engl J Med. 2006; 17. Young J, Povey S. The genetic basis of tuberous sclerosis. Molecular Medicine Today. 1998. 18. de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Vol. 178, American Journal of Medical Genetics, Part C: Seminars in Medical Genetics. 2018. 19. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. The Lancet Neurology. 2015. 20. Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, et al. Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2020.21. Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. Vol. 128, Epilepsy and Behavior. 2022. Annelieke Muller sHL.indd 101 14-11-2023 09:07